Comparison of the pharmacokinetics and tolerability of amlodipine + valsartan, amlodipine + hydrochlorothiazide, valsartan + hydrochlorothiazide, and amlodipine + valsartan + hydrochlorothiazide in patients with hypertension.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amlodipine (Primary) ; Hydrochlorothiazide (Primary) ; Valsartan (Primary)
Indications Hypertension
Focus Pharmacokinetics
Sponsors Novartis Pharmaceuticals Corporation

Most Recent Events

25 Apr 2012 Population pharmacokinetic analysis of hydrochlorothiazide presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
13 Jan 2011 New trial record
17 Sep 2010 Results published in the Journal of Clinical Pharmacology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight